Chengdu Yuandong Biological Pharmaceutical

Chengdu Yuandong Biological Pharmaceutical is a Chinese pharmaceutical company specializing in the development and production of anti-tumor treatments, particularly those derived from traditional Chinese medicine. Founded in 1994 and headquartered in Chengdu, the company is widely recognized for its flagship product, Aidi Injection, which is used as an adjuvant therapy for various cancers including lung and liver cancer. In 2014, the company was acquired by Guizhou Yibai Pharmaceutical, significantly expanding its market reach and resources. Chengdu Yuandong maintains high-standard GMP manufacturing facilities and focuses on the modernization of traditional therapies to meet contemporary clinical needs. The company's portfolio primarily targets oncology and chronic diseases through innovative injectable formulations.